You searched for "Intravitreal injections"
2018 update on intravitreal injections
1 December 2018
| Sofia Rokerya
|
Retina / Uvea / Vitreous
|
Intravitreal injections, Treatment of retinal diseases, Vitreoretinal diseases
In this review article the authors have highlighted the standardised and structured approach to intravitreal injections (IVI) by examining the recent evidence-based literature. IVI is the most commonly performed procedure worldwide with low potential risk of endophthalmitis. IOP spikes are...
An alternative to povidone-iodine for intravitreal injections?
1 February 2017
| Eulee Seow
|
Retina / Uvea / Vitreous
While povidone-iodine (5% aqueous) preparations have historically been considered the most effective antimicrobial prophylaxis for ophthalmic procedures and have been adopted as routine for intravitreal injections, post-procedure pain is a commonly recognized adverse event of IVI and has typically been...
Endophthalmitis after intravitreal injections in France
1 June 2015
| Efrosini Papagiannuli
|
Retina / Uvea / Vitreous
In this nationwide, retrospective, multicentre case series, the authors looked at the incidence and characteristics of endophthalmitis after intravitreal injections of anti-VEGFs and steroids, given for a variety of posterior segment conditions (macular oedema secondary to diabetes or retinal vein...
Antibiotic prophylaxis after intravitreal injections
1 June 2014
| Brian Ang
|
Ophthalmology
The use of topical antibiotics as prophylaxis after intravitreal injections is a contentious issue, especially now with increasing use of intravitreal anti-VEGF agents. In the Wills Eye Institute, prior to May 2011, all patients undergoing intravitreal injections in the office...
G-CSF intravitreal injections for NAION: a pilot study
5 April 2022
| Su Young
|
Neuro-Ophthalmology
|
Anterior ischemic optic neuropathy, Granulocyte colony-stimulating factor, Intravitreal injection, Neuroprotection, Optic atrophy
In rodent models with anterior ischemic optic neuropathy (AION), granulocyte colony-stimulating factor (G-CSF) confers a neuroprotective effect on retinal ganglion cells (RGCs) via anti-apoptotic and anti-inflammatory processes. This prospective study investigated the efficacy of intravitreal injection of G-CSF for the...
Intravitreal injections delivered by ophthalmic clinical nurse specialists
1 June 2015
| Rita McLauchlan, D Armstrong, Konstantinos Balaskas, Sajjad Mahmood
|
EYE - Vitreo-Retinal
Intravitreal injections of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab, for the treatment of wet age-related macular degeneration (AMD) was approved by National Institute for Health & Care Excellence (NICE) in 2008 [1]. The Manchester Royal Eye Hospital (MREH),...
Do bilateral same day intravitreal injections increase the risk of endophthalmitis?
1 February 2019
| Tasmin Berman
|
Retina / Uvea / Vitreous
This large retrospective cohort study reviewed all patients who had bilateral intravitreal anti-vascular endothelial growth factor (VEGF) injections between April 2012 and August 2017. There were 101,932 procedures performed in 5890 patients. The two most common indications for injections were...